Gathering of Pediatric Growth Experts: Exploring the World of Pediatric Growth Hormone Deficiency and Breakthrough Therapies

“Unlocking the Future of Pediatric Growth: Join the Virtual Webinar on September 5, 2023, at 11:00 AM Eastern Time!”

AUSTIN, Texas, Aug. 22, 2023 (GLOBE NEWSWIRE) — Brace yourselves for a groundbreaking event as Lumos Pharma, Inc. (NASDAQ:LUMO), a trailblazing biopharmaceutical company, takes the stage. They’re leading the charge with an oral therapeutic candidate that’s poised to revolutionize the world of moderate Pediatric Growth Hormone Deficiency (PGHD). With Phase 2 clinical trials lighting the path, Lumos Pharma proudly announces a virtual symposium that’s not to be missed. The spotlight shines on an exclusive panel of five pediatric endocrinology luminaries – the true movers and shakers in this dynamic field. They’ll be diving deep into the heart of PGHD, peeling back the layers on the current injectable landscape, and igniting the imagination with the tantalizing prospect of an oral treatment alternative. Mark your calendars for a transformative experience:

PGHD Unveiled: A Journey through Treatment Landscapes and the Oral Frontier

Virtual KOL Webinar Date: Tuesday, September 5, 2023 Time: 11:00 AM – 12:30 PM EDT

Don’t miss your virtual front-row seat! Register now by clicking HERE

This illustrious event assembles the rock stars of pediatric endocrinology, ready to share their wisdom and insights:

Amrit Bhangoo, MD: Section Chair and Director of Research at the Children’s Hospital of Orange County (CHOC), and Associate Professor of Pediatrics at the University of California, Irvine.

Alejandro Diaz, MD: Chief of Pediatric Endocrinology at Niclaus Children’s Pediatric Specialists in Miami, FL.

Erica A. Eugster, MD: Professor of Pediatrics and Division Chief in Pediatric Endocrinology/Diabetology at the Indiana University School of Medicine.

Madhusmita “Madhu” Misra, MD, MPH: Chief of Pediatric Endocrinology at Massachusetts General Hospital, Pediatrician in the Pediatric Endocrinology Program and Diabetes Center at Massachusetts General Hospital, and more.

Kent Reifschneider MD: Associate Professor of Pediatrics at the Children’s Hospital of The King’s Daughters (CHKD), Norfolk, VA.

Get ready for a dynamic discussion as these luminaries converge to enlighten, educate, and engage. But that’s not all! This isn’t a one-way conversation. Following the electrifying panel, brace yourself for a live Q&A session that’s sure to leave you buzzing with insights. Be part of history in the making – reserve your spot now!

About PGHD and the Therapeutic Landscape

“Unlocking the Puzzle of Pediatric Growth: Unveiling the Story of PGHD”

Picture this: a journey of growth stifled, a tale of the pituitary gland’s whispers gone unheard, and the magic of low growth hormone levels playing out in the bodies of children. Welcome to the realm of Pediatric Growth Hormone Deficiency (PGHD), where the curtain rises on a captivating drama of potential unfulfilled. In this tale, the protagonist is growth hormone (GH), the elixir that fuels growth and vitality. But in the shadows, the lack of it gives rise to a symphony of insufficient signals, resulting in growth’s absence on the stage.

As we dive into this narrative, we encounter the current hero of care – a daily injection of external GH, a routine stretching for an average of 7 years. But wait, there’s a twist in the plot! Emerging from the wings are the once-weekly injectable GH therapies, wielding international approval to champion the cause of PGHD. But there’s more to the story – introducing LUM-201, the enigmatic ibutamoren. This oral wonder, a small but potent molecule, holds the key to a new chapter. Its role? Triggering the pituitary gland’s GH secrets, potentially liberating select patients from the routine jabs and injections.

LUM-201 is not just a character; it’s a game-changer. Watch as it takes the stage, amping up the natural rhythm of GH secretion, echoing the body’s own dance of hormones. The outcome? A symphony of potential growth, orchestrated by science and nature alike. The journey to unravel PGHD’s mysteries has only just begun, and LUM-201 is the compass guiding us towards a future where growth is no longer a puzzle, but a promise waiting to be fulfilled.

About Lumos Pharma

Lumos Pharma, Inc. shines as a trailblazing player in the world of biopharmaceuticals, with a laser focus on crafting groundbreaking solutions for rare diseases. Guided by a seasoned management team with a remarkable track record in rare disease drug development, the company’s journey began with a spark of innovation.

At the heart of Lumos Pharma’s mission lies their lead star, LUM-201. Picture this: a revolutionary, oral growth hormone secretagogue that’s set to reshape the landscape of the $4.5 billion global growth hormone market. Say goodbye to needles and injections; LUM-201 aspires to turn the tide, bringing forth a new era of accessible and convenient therapy.

Amidst the excitement, LUM-201 is currently basking in the spotlight of multiple Phase 2 clinical studies, aimed at illuminating its potential in Pediatric Growth Hormone Deficiency (PGHD). Adding to its accolades, this stellar candidate has secured the coveted Orphan Drug Designation on both sides of the Atlantic – a testament to its promise and uniqueness. Lumos Pharma is not just a company; it’s a beacon of hope and innovation in the realm of rare disease therapeutics.

Leave a Comment